Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Tanaproget (NSP-989) is a novel, potent and non-steroidal progesterone receptor agonist that may be utilized as a method of contraception for women. Compared to reference steroidal progestins, it has a higher relative affinity to bind to the PR of different species.
References |
|
---|---|
Additional Infomation |
Tanaproget (NSP-989) is an investigational non-steroidal progestin. It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins. Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.
|
Molecular Formula |
C16H15N3OS
|
---|---|
Molecular Weight |
297.3748
|
Exact Mass |
297.094
|
Elemental Analysis |
C, 64.62; H, 5.08; N, 14.13; O, 5.38; S, 10.78
|
CAS # |
304853-42-7
|
Related CAS # |
304853-42-7
|
PubChem CID |
4369524
|
Appearance |
Light yellow to yellow solid powder
|
LogP |
3.181
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
3
|
Rotatable Bond Count |
1
|
Heavy Atom Count |
21
|
Complexity |
483
|
Defined Atom Stereocenter Count |
0
|
SMILES |
N#CC1=CC=C(C2=CC=C(NC(OC3(C)C)=S)C3=C2)N1C
|
InChi Key |
PYVFWTPEBMRKSR-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21)
|
Chemical Name |
5-(4,4-dimethyl-2-sulfanylidene-1H-3,1-benzoxazin-6-yl)-1-methylpyrrole-2-carbonitrile
|
Synonyms |
Tanaproget; NSP 989; NSP-989; NSP989
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL (~168.1 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3628 mL | 16.8141 mL | 33.6281 mL | |
5 mM | 0.6726 mL | 3.3628 mL | 6.7256 mL | |
10 mM | 0.3363 mL | 1.6814 mL | 3.3628 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.